Cargando…

Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis

OBJECTIVES: To determine the potential of intravoxel incoherent motion (IVIM) MR imaging for staging of hepatic fibrosis (HF). METHODS: We searched PubMed and EMBASE from their inception to 31 July 2015 to select studies reporting IVIM MR imaging and HF staging. We defined F1-2 as non-advanced HF, F...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bin, Liang, Long, Dong, Yuhao, Lian, Zhouyang, Chen, Wenbo, Liang, Changhong, Zhang, Shuixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731200/
https://www.ncbi.nlm.nih.gov/pubmed/26820668
http://dx.doi.org/10.1371/journal.pone.0147789
_version_ 1782412519446413312
author Zhang, Bin
Liang, Long
Dong, Yuhao
Lian, Zhouyang
Chen, Wenbo
Liang, Changhong
Zhang, Shuixing
author_facet Zhang, Bin
Liang, Long
Dong, Yuhao
Lian, Zhouyang
Chen, Wenbo
Liang, Changhong
Zhang, Shuixing
author_sort Zhang, Bin
collection PubMed
description OBJECTIVES: To determine the potential of intravoxel incoherent motion (IVIM) MR imaging for staging of hepatic fibrosis (HF). METHODS: We searched PubMed and EMBASE from their inception to 31 July 2015 to select studies reporting IVIM MR imaging and HF staging. We defined F1-2 as non-advanced HF, F3-4 as advanced HF, F0 as normal liver, F1 as very early HF, and F2-4 as significant HF. Then we compared stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using IVIM-derived parameters (pseudo-diffusion coefficient D*, perfusion fraction f, and pure molecular diffusion parameter D). The effect estimate was expressed as a pooled weighted mean difference (WMD) with 95% confidence interval (CI), using the fixed-effects model. RESULTS: Overall, we included six papers (406 patients) in this study. Significant differences in D* were observed between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 2.46, 95% CI 0.83–4.09, P = 0.006; WMD 13.10, 95% CI 9.53–16.67, P < 0.001; WMD 14.34, 95% CI 10.26–18.42, P < 0.001, respectively). Significant differences in f were also found between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 1.62, 95% CI 0.06–3.18, P = 0.027; WMD 5.63, 95% CI 2.74–8.52, P < 0.001; WMD 3.30, 95% CI 2.10–4.50, P < 0.001, respectively). However, D showed no differences between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 0.05, 95% CI -0.01─0.11, P = 0.105; WMD 0.04, 95% CI -0.01─0.10, P = 0.230; WMD 0.02, 95% CI -0.02─0.06, P = 0.378, respectively). CONCLUSIONS: IVIM MR imaging provides an effective method of staging HF and can distinguish early HF from normal liver, significant HF from normal liver or very early HF, and advanced HF from non-advanced HF.
format Online
Article
Text
id pubmed-4731200
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47312002016-02-04 Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis Zhang, Bin Liang, Long Dong, Yuhao Lian, Zhouyang Chen, Wenbo Liang, Changhong Zhang, Shuixing PLoS One Research Article OBJECTIVES: To determine the potential of intravoxel incoherent motion (IVIM) MR imaging for staging of hepatic fibrosis (HF). METHODS: We searched PubMed and EMBASE from their inception to 31 July 2015 to select studies reporting IVIM MR imaging and HF staging. We defined F1-2 as non-advanced HF, F3-4 as advanced HF, F0 as normal liver, F1 as very early HF, and F2-4 as significant HF. Then we compared stage F0 with F1, F0-1 with F2-3, and F1-2 with F3-4 using IVIM-derived parameters (pseudo-diffusion coefficient D*, perfusion fraction f, and pure molecular diffusion parameter D). The effect estimate was expressed as a pooled weighted mean difference (WMD) with 95% confidence interval (CI), using the fixed-effects model. RESULTS: Overall, we included six papers (406 patients) in this study. Significant differences in D* were observed between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 2.46, 95% CI 0.83–4.09, P = 0.006; WMD 13.10, 95% CI 9.53–16.67, P < 0.001; WMD 14.34, 95% CI 10.26–18.42, P < 0.001, respectively). Significant differences in f were also found between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 1.62, 95% CI 0.06–3.18, P = 0.027; WMD 5.63, 95% CI 2.74–8.52, P < 0.001; WMD 3.30, 95% CI 2.10–4.50, P < 0.001, respectively). However, D showed no differences between F0 and F1, F0-1 and F2-3, and F1-2 and F3-4 (WMD 0.05, 95% CI -0.01─0.11, P = 0.105; WMD 0.04, 95% CI -0.01─0.10, P = 0.230; WMD 0.02, 95% CI -0.02─0.06, P = 0.378, respectively). CONCLUSIONS: IVIM MR imaging provides an effective method of staging HF and can distinguish early HF from normal liver, significant HF from normal liver or very early HF, and advanced HF from non-advanced HF. Public Library of Science 2016-01-28 /pmc/articles/PMC4731200/ /pubmed/26820668 http://dx.doi.org/10.1371/journal.pone.0147789 Text en © 2016 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zhang, Bin
Liang, Long
Dong, Yuhao
Lian, Zhouyang
Chen, Wenbo
Liang, Changhong
Zhang, Shuixing
Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title_full Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title_fullStr Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title_full_unstemmed Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title_short Intravoxel Incoherent Motion MR Imaging for Staging of Hepatic Fibrosis
title_sort intravoxel incoherent motion mr imaging for staging of hepatic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731200/
https://www.ncbi.nlm.nih.gov/pubmed/26820668
http://dx.doi.org/10.1371/journal.pone.0147789
work_keys_str_mv AT zhangbin intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT lianglong intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT dongyuhao intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT lianzhouyang intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT chenwenbo intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT liangchanghong intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis
AT zhangshuixing intravoxelincoherentmotionmrimagingforstagingofhepaticfibrosis